LAVA Therapeutics N.V.
News
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, LAVA ), a clinical-stage immuno-oncology company focused on developing its...\n more…
LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities
Ticker Report JMP Securities reaffirmed their market outperform rating on shares of LAVA Therapeutics (NASDAQ:LVTX - Free Report) in a research note released on Wednesday morning, Benzinga reports. JMP Securities...\n more…
LAVA Therapeutics Second Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.48 loss in 2Q 2023)
Simply Wall St LAVA Therapeutics ( NASDAQ:LVTX ) Second Quarter 2024 Results Key Financial Results Net loss: US$8.30m (loss narrowed...\n more…
LAVA Therapeutics (NASDAQ:LVTX) Issues Earnings Results
Ticker Report LAVA Therapeutics (NASDAQ:LVTX - Get Free Report) released its earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus...\n more…
LAVA Therapeutics (NASDAQ:LVTX) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS
Ticker Report LAVA Therapeutics (NASDAQ:LVTX - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus...\n more…
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy
Zacks Investment Research LAVA Therapeutics N.V. (LVTX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings...\n more…